CPHI (China Pharma Holding) Total Equity: $37.02 Mil (As of Mar. 2026)


CPHI China Pharma Holding Inc CPHI
26 GF Score
Price $0.57
GF Value $0.24
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is China Pharma Holding Total Equity?

China Pharma Holding CPHI -10.97% 26 Total Equity is $37.02 Mil as of Mar. 2026. GuruFocus rates CPHI with a GF Score™ of 26/100 and a GF Value™ of $0.24 (Significantly Overvalued). The stock has 3 warning signs investors should review.

China Pharma Holding's total equity for the quarter that ended in Mar. 2026 was $37.02 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

China Pharma Holding Total Equity Historical Data

* Premium members only.

The historical data trend for China Pharma Holding's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Pharma Holding Total Equity Chart

China Pharma Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.02 4.29 7.46 7.75 22.74

China Pharma Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.97 6.46 8.31 22.74 37.02
CPHI
26GF Score
China Pharma Holding Inc CPHI
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Pharma Holding Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

China Pharma Holding's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=30.999-8.26
=22.74

China Pharma Holding's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=45.144-8.12
=37.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $37.02 Mil mean?
China Pharma Holding (CPHI) has a Total Equity of $37.02 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for China Pharma Holding and its competitors.
Is China Pharma Holding's Total Equity too high?
China Pharma Holding's current Total Equity is $37.02 Mil. Overall, China Pharma Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Total Equity compare to TXMD and RMTI?
China Pharma Holding's Total Equity of $37.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for China Pharma Holding and its competitors. China Pharma Holding's current Total Equity is $37.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
Based on GuruFocus' analysis, China Pharma Holding (CPHI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.57 — trading 137.5% above its estimated fair value. The current Total Equity is $37.02 Mil. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For China Pharma Holding (CPHI), the current Total Equity is $37.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Pharma Holding (CPHI) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24. GuruFocus considers China Pharma Holding to be Significantly Overvalued.

Key valuation signals for CPHI:

  • Total Equity: $37.02 Mil
  • GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score

Get the complete analysis for CPHI

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price
$0.24
GF Value